Showing 711-720 of 6036 results for "".
The SpyGlass Pharma™ Drug Delivery Platform
https://modernod.com/articles/visionary-breakthroughs/the-spyglass-pharma-drug-delivery-platform-1/39826/Drug delivery integrated into the cataract surgery workflow.Watch for Complications of Systemic Meds
https://beta.modernod.com/articles/significant-findings/watch-for-complications-of-systemic-meds/39848/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatNewborn Eye Protection at Stake in WVa
https://modernod.com/articles/significant-findings/newborn-eye-protection-at-stake-in-wva/37834/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatThe Near Future in Managing Dry Eye Disease
https://modernod.com/topics/corneaanterior-segment/the-near-future-in-managing-dry-eye-disease-1/36877/Cecelia Koetting, OD, FAAO, DipABO, and Marc Bloomenstein, OD, FAAO, convened to discuss the current state of ocular surface disease, including the progressive nature, patient communication and symptoms, new and upcoming therapies, and more.Got a Corneal Wound? Breast Milk Could Help
https://modernod.com/articles/significant-findings/got-a-corneal-wound-breast-milk-could-help/37826/Significant Findings is MOD's weekly email newsletter for progressive-minded, full scope optometrists. Delivered to your inbox every Monday, Significant Findings offers fresh insights on the latest industry news, life anecdotes, current events related to the practice of optometry, and more—all curatAldeyra Resubmits NDA for DED Drug Reproxalap
https://modernod.com/podcasts/eyewire-news-the-podcast/aldeyra-resubmits-nda-for-ded-drug-reproxalap/37053/Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.Water-Free Ciclosporin-Based Eye Drop for DED Approved in Europe
https://modernod.com/podcasts/eyewire-news-the-podcast/water-free-ciclosporin-based-eye-drop-for-ded-approved-in-europe/37052/Novaliq’s water-free ciclosporin-based eye drop for dry eye disease is approved in Europe; the FDA approves first new ophthalmic steroid in over 15 years; and the first slit-lamp mounted rebound tonometer is launched in the US and Europe.Bitot Spots
https://modernod.com/topics/ocular-surface/bitot-spots/38856/Malnutrition leads to atypical ocular surface disease.A Place for House Calls in Optometry
https://modernod.com/topics/patient-care/a-place-for-house-calls-in-optometry/38789/Consider delivering eye care where it’s needed most.Geographic Atrophy in the Primary Eye Care Clinic: Improving Detection, Understanding Therapy, and Perfecting the Referral
https://modernod.com/mod-issues/supplements-inserts/geographic-atrophy-in-the-primary-eye-care-clinic-improving-detection-understanding-therapy-and-perfecting-the-referral/38778/